A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents (MATCH-R)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02517892|
Recruitment Status : Unknown
Verified February 2021 by Gustave Roussy, Cancer Campus, Grand Paris.
Recruitment status was: Recruiting
First Posted : August 7, 2015
Last Update Posted : February 25, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This is a prospective study to identify molecular mechanisms of acquired resistance to targeted therapies in patients with unresectable or metastatic cancer.
This is a protocol to study clinical characteristics and biopsy tissue of patients with oncogene-driven cancer who have had previous clinical response to targeted therapy and subsequently experience progression of disease. The tissues and other specimens will be used to carry out laboratory studies to explore the molecular basis of acquired resistance to targeted therapies.
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Oncogen-driven Cancer||Procedure: Biopsy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1500 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents|
|Actual Study Start Date :||December 18, 2014|
|Estimated Primary Completion Date :||December 2022|
|Estimated Study Completion Date :||December 2022|
|Experimental: Patients with metastatic oncogen-driven cancer||
- Type and frequency of molecular alterations in resistant tumors using whole exome sequencing [ Time Frame: 30 days after inclusion ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Patients diagnosed with confirmed cancer and who fulfill the following eligibility criteria will be considered eligible for this study:
- Patient affiliated to a social security regimen
- Patients scheduled to receive anticancer agents or currently receiving anticancer agents
- Tumor lesion accessible to core biopsies (malignant effusions can represent an alternative)
- Patient who is fully informed, able to comply with the protocol and who signed the informed consent.
- Availability of initial tumor material (ideally frozen, or non-Bouin fixed paraffin embedded material) acquired before exposure to the targeted therapy Note: Patients may have received other treatments since treatment with targeted therapies including radiation or chemotherapy, before undergoing the study biopsy.
1. Coagulation abnormality prohibiting a biopsy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02517892
|Contact: Antoine ITALIANO, MD-PhD||0142114211 ext +firstname.lastname@example.org|
|Contact: Aurélie Abou Lovergne||0142113862 ext +33||aurélie.email@example.com|
|Gustave Roussy Cancer Campus Grand Paris||Recruiting|
|Villejuif, Val De Marne, France, 94805|
|Contact: Jean Charles Soria, MD-PhD 0142114391 ext +33 firstname.lastname@example.org|
|Contact: Aurélie Abou Lovergne 0142113862 ext +33 email@example.com|
|Responsible Party:||Gustave Roussy, Cancer Campus, Grand Paris|
|Other Study ID Numbers:||
2014/2144 ( Other Identifier: CSET number )
|First Posted:||August 7, 2015 Key Record Dates|
|Last Update Posted:||February 25, 2021|
|Last Verified:||February 2021|